New Information Campaigns…”Can’t Pass It On” and “U=U”

There are a couple of campaigns that are trying to reduce the stigma associated with HIV. Both have the same message, but use different slogans. THT has a campaign called “Can’t Pass it on”: http://www.tht.org.uk/sexual-health/About-HIV/Can_apos_t-Pass-It-On?utm_source=Terrence%20Higgins%20Trust%20newsletters&utm_medium=email&utm_campaign=8390497_Can%27t%20Pass%20It%20On%20launch%20-%20members%20and%20volunteers&dm_i=5HE,4ZU5D,GNFZ55,J0X60,1 They say: Medical evidence has shown that people on effective HIV treatment can’t pass it on. If everyone knew this, we […]

Bone Fractures Occur at an Earlier Age Among Men with HIV

Rates of osteopenia (low bone mineral density – BMD) and osteoporosis are higher in people living with HIV (PLWH) than in the general population. It’s possible that HIV itself or the body’s response to HIV may contribute to bone problems. In addition, many people living with HIV smoke, drink, don’t get enough exercise or have […]

Breathlessness, coughing and respiratory problems

Thanks to ART, many HIV-positive people now have a near-normal life expectancy. However, rates of heart, liver and kidney disease remain higher, compared with the general population. Research involving US military veterans also found that HIV-positive people had a significantly higher rate of chronic obstructive pulmonary disease (COPD). Investigators at the Royal Free Hospital, London, wanted to further […]

Switching from Efavirenz Does Not Improve Cognitive Function

Despite effective antiretroviral therapy (ART), mild cognitive impairment (things like decreased attention span, poorer memory, worse problem-solving ability) remains common in people living with HIV. The reasons for this are poorly understood and little is known about the impact of specific anti-HIV drugs on neurological function. However, efavirenz – one of the most commonly used antiretrovirals […]

Generic HIV Drugs

The financial pressures faced by HIV clinics in the NHS was a major theme of the recent British HIV Association conference. Doctors discussed how they can keep costs down without compromising the quality of care. One of the most important ways they can do so is to switch some patients from branded, expensive drugs to […]

Co-infection with HCV increases cancer risk for people with HIV

As a result of highly-active antiretroviral therapy (HAART), many people with HIV now have a near-normal life expectancy. However, rates of serious non-HIV-related illnesses are higher among people with HIV compared to individuals in the general population. Several studies have shown that even for people taking effective HAART, they have higher risk of several malignancies not traditionally associated […]

New version of Tenofovir

Tenofovir disoproxil fumarate (TDF) is one of the most widely used antiretroviral drugs. It is highly effective in treating HIV,and for most people, generally safe and well-tolerated. However, in a small minority of cases it can cause kidney problems. And TDF has an impact on bones…for most people, this is small and not noticeable, but […]

Two-drug Regimen Maintains Viral Suppression

Normal treatment for HIV involves taking three drug – so-called “triple therapy”, HAART, or cART. Whilst this is good for keeping the virus suppressed – so that the viral load is undetectable – taking three drugs can sometimes lead to side-effects. So work is being done to see if the drug burden can be reduced […]

Large Drop in HIV Diagnoses in London gay men 

  Four sexual health clinics serving large numbers of gay men in London have reported that they diagnosed far fewer gay men with HIV during 2016 than they did during 2015.  Many doctors believe that the use of pre-exposure prophylaxis (PrEP) is part of the explanation for these reductions. Such large drops in new diagnoses are […]